Venaxis (APPY -9.6%) slips today, despite its announcement late yesterday that European regulators have approved the company's blood-based appendicitis test APPY1. Initial sales are slated to begin during Q1 in key territories, including the UK, Italy, France, Germany and Benelux countries. The company expects to announce agreements with top EU distributors beginning in the first quarter 2013.
Venaxis (APPY -9.6%) slips today, despite its announcement late yesterday that European...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs